NFKB1 and Behcet disease: Furthermore, TNF-α concentration was found positively correlated with BD activity in a cross-sectional, blinded study.[28] Therapeutic administration of TNF-α blockers has been successfully used to treat various manifestations of BD.[29] TNF-α exerts pro-inflammatory effects via binding to tumor necrosis factor receptor which activates the NF-κB pathway.[30] In our study, TNF ranked first among the core targets, indicating its critical role in TWH treatment for BD.